Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
26
CABA Quote, Financials, Valuation and Earnings
Last price:
$1.76
Seasonality move
:
14.22%
Day range:
$1.72 - $1.81
52-week range:
$0.99 - $9.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.73x
Volume:
1M
Avg. volume:
3M
1-year change:
-79.36%
Market cap:
$88.8M
Revenue:
--
EPS (TTM):
-$2.54
Analysts' Opinion
-
Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.67, Cabaletta Bio has an estimated upside of 795.24% from its current price of $1.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.75.
Fair Value
-
According to the consensus of 9 analysts, Cabaletta Bio has 795.24% upside to fair value with a price target of $15.67 per share.
CABA vs. S&P 500
-
Over the past 5 trading days, Cabaletta Bio has underperformed the S&P 500 by -12.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cabaletta Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cabaletta Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Cabaletta Bio reported revenues of --.
Earnings Growth
-
Cabaletta Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cabaletta Bio reported earnings per share of -$0.71.
Enterprise value:
-43M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$58.1M | -$85.7M | -$134.2M | -$28M | -$37.1M | |
| EBITDA | -$56.8M | -$74.3M | -$120.9M | -$24.7M | -$35.2M | |
| Diluted EPS | -$1.81 | -$1.72 | -$2.54 | -$0.51 | -$0.71 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $105.8M | $111.4M | $95.7M | $227.5M | $134.6M | |
| Total Assets | $107.3M | $113.7M | $103.4M | $240.5M | $165.1M | |
| Current Liabilities | $4M | $6.9M | $9.3M | $18M | $34M | |
| Total Liabilities | $4M | $6.9M | $11.8M | $18.7M | $43.6M | |
| Total Equity | $103.3M | $106.7M | $91.7M | $221.7M | $121.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$46.2M | -$64.9M | -$95M | -$24M | -$30.8M | |
| Cash From Investing | $47.3M | -$47.9M | $47.3M | -$812K | -$785K | |
| Cash From Financing | $33.2M | $194.3M | $4.3M | $6.9M | -$552K | |
| Free Cash Flow | -$48.9M | -$66M | -$97.2M | -$24.8M | -$31.6M | |
CABA
Sector
Market Cap
$88.8M
$32.8M
Price % of 52-Week High
19.34%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-79.36%
-35.38%
Beta (5-Year)
2.808
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.83
200-day SMA
Sell
Level
$2.66
Bollinger Bands (100)
Sell
Level
1.31 - 2.21
Chaikin Money Flow
Sell
Level
-41.2M
20-day SMA
Sell
Level
$1.98
Relative Strength Index (RSI14)
Sell
Level
46.44
ADX Line
Sell
Level
25.38
Williams %R
Buy
Level
-81.5534
50-day SMA
Buy
Level
$1.61
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
89.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Stock Forecast FAQ
In the current month, CABA has received 7 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CABA average analyst price target in the past 3 months is $15.67.
-
Where Will Cabaletta Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cabaletta Bio share price will rise to $15.67 per share over the next 12 months.
-
What Do Analysts Say About Cabaletta Bio?
Analysts are divided on their view about Cabaletta Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cabaletta Bio is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Cabaletta Bio's Price Target?
The price target for Cabaletta Bio over the next 1-year time period is forecast to be $15.67 according to 9 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CABA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cabaletta Bio is a Buy. 7 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CABA?
You can purchase shares of Cabaletta Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cabaletta Bio shares.
-
What Is The Cabaletta Bio Share Price Today?
Cabaletta Bio was last trading at $1.76 per share. This represents the most recent stock quote for Cabaletta Bio. Yesterday, Cabaletta Bio closed at $1.75 per share.
-
How To Buy Cabaletta Bio Stock Online?
In order to purchase Cabaletta Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 0.67% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 3.79% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 12.45% over the past day.
